Insights

Strategic Partnerships Tango Therapeutics has a track record of forming strategic partnerships with reputable institutes like the Institute of Molecular Biology and the Vienna BioCenter Core Facilities, indicating a potential sales opportunity to collaborate on research projects or licensing agreements.

Financial Growth With recent private placement financing of $80 million, Tango Therapeutics demonstrates strong financial backing and growth potential. This presents a sales opportunity for financial services offering investment solutions or for vendors providing services to rapidly expanding companies.

Key Personnel Addition The appointment of Adam Crystal, M.D., Ph.D., as President of Research and Development highlights Tango's focus on leadership expertise. Engaging with key personnel like Adam Crystal could open up sales avenues for consulting services, research collaborations, or specialized training programs.

Innovative Technology Stack Tango Therapeutics leverages advanced technology tools such as Cloudflare, jQuery, and Drupal Multisite in their tech stack. Tech companies can explore sales opportunities by offering complementary software solutions, cybersecurity services, or website optimization tools to enhance Tango's operations.

Pipeline Expansion Tango Therapeutics is actively working on developing breakthrough medicines in new areas of cancer treatment, offering potential sales opportunities for suppliers of laboratory equipment, contract research organizations, or pharmaceutical companies looking to collaborate on drug development projects.

Tango Therapeutics Tech Stack

Tango Therapeutics uses 8 technology products and services including Cloudflare, Font Awesome, jQuery, and more. Explore Tango Therapeutics's tech stack below.

  • Cloudflare
    Content Management System
  • Font Awesome
    Font Scripts
  • jQuery
    Javascript Libraries
  • Acquia Cloud Platform
    Platform As A Service
  • HSTS
    Security
  • Akamai Bot Manager
    Security
  • Drupal Multisite
    Web Hosting
  • Draftpress HFCM
    Web Platform Extensions

Media & News

Tango Therapeutics's Email Address Formats

Tango Therapeutics uses at least 1 format(s):
Tango Therapeutics Email FormatsExamplePercentage
FLast@tangotx.comJDoe@tangotx.com
95%
First_L@tangotx.comJohn_D@tangotx.com
3%
FL@tangotx.comJD@tangotx.com
1%
First.Last@tangotx.comJohn.Doe@tangotx.com
1%

Frequently Asked Questions

Where is Tango Therapeutics's headquarters located?

Minus sign iconPlus sign icon
Tango Therapeutics's main headquarters is located at 201 Brookline Ave Suite 901 Boston, Massachusetts 02215 US. The company has employees across 4 continents, including North AmericaSouth AmericaAfrica.

What is Tango Therapeutics's stock symbol?

Minus sign iconPlus sign icon
Tango Therapeutics is a publicly traded company; the company's stock symbol is TNGX.

What is Tango Therapeutics's official website and social media links?

Minus sign iconPlus sign icon
Tango Therapeutics's official website is tangotx.com and has social profiles on LinkedIn.

How much revenue does Tango Therapeutics generate?

Minus sign iconPlus sign icon
As of October 2024, Tango Therapeutics's annual revenue reached $35M.

What is Tango Therapeutics's SIC code NAICS code?

Minus sign iconPlus sign icon
Tango Therapeutics's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Tango Therapeutics have currently?

Minus sign iconPlus sign icon
As of October 2024, Tango Therapeutics has approximately 176 employees across 4 continents, including North AmericaSouth AmericaAfrica. Key team members include Chief Scientific Officer: J. N. A.Chief Development Operations Officer: H. D.Chief Scientific Officer: A. H.. Explore Tango Therapeutics's employee directory with LeadIQ.

What industry does Tango Therapeutics belong to?

Minus sign iconPlus sign icon
Tango Therapeutics operates in the Biotechnology Research industry.

What technology does Tango Therapeutics use?

Minus sign iconPlus sign icon
Tango Therapeutics's tech stack includes CloudflareFont AwesomejQueryAcquia Cloud PlatformHSTSAkamai Bot ManagerDrupal MultisiteDraftpress HFCM.

What is Tango Therapeutics's email format?

Minus sign iconPlus sign icon
Tango Therapeutics's email format typically follows the pattern of . Find more Tango Therapeutics email formats with LeadIQ.

How much funding has Tango Therapeutics raised to date?

Minus sign iconPlus sign icon
As of October 2024, Tango Therapeutics has raised $186M in funding. The last funding round occurred on Aug 11, 2021 for $186M.

When was Tango Therapeutics founded?

Minus sign iconPlus sign icon
Tango Therapeutics was founded in 2017.
Tango Therapeutics

Tango Therapeutics

Biotechnology ResearchMassachusetts, United States51-200 Employees

Tango Therapeutics is a biotechnology company discovering and developing novel medicines targeting cancer vulnerabilities to deliver transformational new therapies for patients.

Tango was launched in 2017 with a $55 million Series A investment from Third Rock Ventures. The company has established a robust product engine that leverages advances in DNA sequencing and CRISPR-based target discovery to generate breakthrough medicines that have the potential to provide deeper, more sustained benefit than today’s targeted therapies, and extend the benefit of available immuno-oncology agents.

Tango Therapeutics is focused on three areas of drug development, each in well-defined patient populations currently lacking effective treatment options, and each with hallmarks of cancer that have not been targeted yet. These include: loss of tumor suppressor gene function; multiple oncogenic drivers; and immune evasion.

What fuels each of Tango’s programs is an increasingly sophisticated ability to utilize synthetic lethality - the interaction between two genes that causes cell death when both are inactivated. In cancer cells, one of these genes is inactivated by mutation; the other will be inactivated by a drug.  This approach leaves normal cells largely unaffected, with the potential to greatly enhance anti-tumor efficacy and reduce associated toxicity.  

Tango’s success will be driven by its depth of understanding of the genetic subtypes of cancer, and corresponding insights into novel drug targets and combinations uniquely relevant to each subtype. By shaping discovery efforts in this way, Tango has the potential to reach the clinic quickly, and with a clear plan for identifying the patients most likely to benefit from each new treatment, an approach that could increase both speed and probability of success in translating novel target discoveries into transformational new medicines for patients.

Section iconCompany Overview

Headquarters
201 Brookline Ave Suite 901 Boston, Massachusetts 02215 US
SIC Code
8733 - Noncommercial Research Organizations
Stock Symbol
TNGX
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2017
Employees
51-200

Section iconFunding & Financials

  • $186M

    Tango Therapeutics has raised a total of $186M of funding over 4 rounds. Their latest funding round was raised on Aug 11, 2021 in the amount of $186M.

  • $10M$50M

    Tango Therapeutics's revenue is in the range of $10M$50M

Section iconFunding & Financials

  • $186M

    Tango Therapeutics has raised a total of $186M of funding over 4 rounds. Their latest funding round was raised on Aug 11, 2021 in the amount of $186M.

  • $10M$50M

    Tango Therapeutics's revenue is in the range of $10M$50M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.